The Poly [ADP Ribose] Polymerase 3 pipeline drugs market research report outlays comprehensive information on the Poly [ADP Ribose] Polymerase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Poly [ADP Ribose] Polymerase 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Cardiovascular which include the indications Fallopian Tube Cancer, Peritoneal Cancer, and Pulmonary Arterial Hypertension. It also reviews key players involved in Poly [ADP Ribose] Polymerase 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Poly [ADP Ribose] Polymerase 3 pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, and Preclinical stages are 2, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Poly [ADP Ribose] Polymerase 3 overview
Poly [ADP Ribose] Polymerase 3 (PARP3) is a member of the PARP family of enzymes that function as key regulators in the DNA damage response. PARP3 is primarily involved in the repair of DNA lesions and maintaining genomic stability. Upon sensing DNA damage, PARP3 catalyses the addition of poly(ADP-ribose) chains to target proteins, a process known as poly(ADP-ribosylation). This post-translational modification facilitates the recruitment of DNA repair factors to the damaged sites, promoting the efficient repair of single-strand breaks. PARP3 has been implicated in various DNA repair pathways, including base excision repair and the alternative non-homologous end-joining pathway. Its role in these processes makes PARP3 a crucial component in the cellular defence against genotoxic stress. Additionally, PARP3 has been associated with the regulation of other cellular functions, including transcriptional regulation and chromatin remodelling.
For a complete picture of Poly [ADP Ribose] Polymerase 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
